Arvinas (NASDAQ:ARVN) stock tumbled on Thursday after the company announced almost one-third workforce reduction and removed ...

Discover why biotech stock ARVN, trading at a 70% discount to cash value, offers potential upside despite setbacks.

The state of Connecticut “WARN” site that reports such layoffs indicates that 92 of the people to be laid off are state ...

New Haven-based Arvinas will lay off 131 employees, with 92 in Connecticut, as part of a major workforce reduction.

Main Capital, a boutique investment firm, released its first-quarter 2025 investor letter. A copy of the letter can be ...

Arvinas (NASDAQ:ARVN) is scheduled to announce Q1 earnings results on Thursday, May 1st, before market open. The consensus EPS Estimate is -$0.97 and the consensus Revenue Estimate is $41.87M (+65.5% ...

New Haven-based biotech company Arvinas Inc. announced Thursday that it’s cutting 131 employees, or about a third of its workforce.  The layoffs, which include 92 Connecticut residents, are intended ...

There's been a notable change in appetite for Arvinas, Inc. (NASDAQ:ARVN) shares in the week since its first-quarter report, with the stock down 15% to US$7.72. Revenues of 351% beat expectations by ...

Arvinas, Inc., a biotechnology company focused on targeted protein degradation therapies, announced that new preclinical data for its investigational drug ARV-393 will be presented at the upcoming ...

Arvinas will present Phase 3 VERITAC-2 trial results for vepdegestrant at ASCO 2025, evaluating its effectiveness in breast cancer treatment. Arvinas, Inc. announced that it will present the ...

Ratings for Arvinas ARVN were provided by 25 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings ...

The latest price target for Arvinas (NASDAQ:ARVN) was reported by Morgan Stanley on May 9, 2025. The analyst firm set a price target for $11.00 expecting ARVN to rise to within 12 months (a ...